Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Key Inclusion Criteria:

• Urinary Incontinence for at least 3 months prior to Screening as a result ofNeurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.
• Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level orbelow which occurred at least 6 months prior to Screening.
• Subjects with Multiple Sclerosis must be clinically stable in the investigator'sopinion, with no exacerbation (relapse) of MS for at least 3 months prior toScreening.
• Subjects must have had an inadequate response after at least 4 weeks of oralmedications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists)and/or have intolerable side-effects.
• Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequatebladder emptying.
• An average of at least two episodes per day of Urinary Incontinence recorded on thescreening bladder diary.

Key Exclusion Criteria:

• Any current condition (other than NDO) that may impact on bladder function.
• Previous or current, tumour or malignancy affecting the spinal column or spinal cord,or any other unstable cause of SCI.
• Any condition that will prevent cystoscopic treatment administration or CIC usage,e.g. urethral strictures.
• Current indwelling bladder catheter, or removal of indwelling bladder catheter lessthan 4 weeks prior to Screening.
• BTX-A treatment within 9 months prior to Screening for any urological condition (e.g.detrusor or urethral sphincter treatments).
• Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within 4 weeks prior to Screening. Any implanted neuromodulation device must be switched offat least 4 weeks prior to Screening.